This study was aimed to examine whether a volatile anesthetic sevoflurane in clinical doses reduces vasoconstriction under the inhibition of phosphatidylinositol 3-kinase (PI3K) in the rat and human arteries and whether the intravenous administration of the PI3K inhibitor decreases blood pressure in rats under the sevoflurane inhalation.Materials and methods:
Rat arteries (n = 5–6) and human omental arteries (n = 5–6) were subjected to isometric force recordings and western immunoblotting for Rho kinase, mitogen-activated protein kinase, and protein kinase C. Some arteries were incubated with sevoflurane (1.5% or 3%), a selective PI3K inhibitor LY294002 (3 × 10− 6 mol/L) or the combination. Mean arterial pressure (MAP) and heart rate (HR) in rats (n = 7) were evaluated with or without intravenous injection of LY294002 (3 × 10− 6 mol/L) under 2% sevoflurane inhalation.Key findings:
Sevoflurane with LY294002, but not sevoflurane or LY294002 solely, inhibited the phenylephrine-induced contraction (32% to 52% decrease at phenylephrine [3 × 10− 6 mol/L] in rat arteries and [3 × 10− 5 mol/L] in human arteries). Sevoflurane (3%) only with LY294002 decreased Rho kinase activity in the rat aorta into 30%. Intravenous LY294002 reduced MAP (8.1–12.4 mm Hg decrease), but not HR, in rats under 2% sevoflurane inhalation.Significance:
Clinical sevoflurane doses with PI3K inhibition reduce the contraction of rat and human arteries ex vivo resulting from Rho kinase inhibition, and systemic blood pressure of rats in vivo. These results suggest that sevoflurane potentially causes vasodilation and hypotension in patients receiving anti-cancer therapy that inhibits PI3K.